NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Excluding the current phase three trial, clinical and compassionate use over the past ten years = over 200 patients amounting to 1000 treatments. The Response Rate was consistently approximately 80% of the total pool. Only one possibly related serious adverse event. The compassionate use program covers a broad range of cancers including but not limited to GBM* cancer.

From January 2014 webcast.


* We know from other sources that GBM is one of the types of cancers treated through NWBO's compassionate use program.